VRK2 identifies a subgroup of primary high-grade astrocytomas with a better prognosis - Wikidata - wikimedia - TriplyDB

VRK2 identifies a subgroup of primary high-grade astrocytomas with a better prognosis

VRK2 identifies a subgroup of primary high-grade astrocytomas with a better prognosis

http://www.wikidata.org/entity/Q35002396

about

Vaccinia-related kinase 1 (VRK1) confers resistance to DNA-damaging agents in human breast cancer by affecting DNA damage response Predictive value of vrk 1 and 2 for rectal adenocarcinoma response to neoadjuvant chemoradiation therapy: a retrospective observational cohort study Functional characterization of lysosomal interaction of Akt with VRK2.

P2860

Q33688463-814589D9-1D70-4402-9346-7A8E675152DB Q36085189-09A5C571-4824-42DB-B563-2D5769C23F0C Q54976940-F6A0ECE1-FDBE-4BAF-AE11-40CC64499722

P2860

VRK2 identifies a subgroup of primary high-grade astrocytomas with a better prognosis

http://www.wikidata.org/entity/Q35002396

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

VRK2 identifies a subgroup of primary high-grade astrocytomas with a better prognosis

@ast

VRK2 identifies a subgroup of primary high-grade astrocytomas with a better prognosis

@en

type

label

VRK2 identifies a subgroup of primary high-grade astrocytomas with a better prognosis

@ast

VRK2 identifies a subgroup of primary high-grade astrocytomas with a better prognosis

@en

prefLabel

VRK2 identifies a subgroup of primary high-grade astrocytomas with a better prognosis

@ast

VRK2 identifies a subgroup of primary high-grade astrocytomas with a better prognosis

@en

P1433

Q35002396-B23B3162-E4B7-4AB5-A0CF-C7B2871D05C3

P1476

Q35002396-B0329A2C-1188-4984-98E2-AD5B91CA16C0

P2093

Q35002396-0198BB9A-2BE0-4608-9A3D-74DDD5E1D20B

Q35002396-19CB7027-4D56-4407-92A8-BC88A3438E3B

Q35002396-4E981AE1-9FC6-4A9D-B809-95F81C32E548

Q35002396-6ECD4938-2216-45EA-8B37-13D9C58D243F

Q35002396-82FCA2F8-39A8-41FB-AE95-4FBEB64ACA46

P2860

Q35002396-03585B7D-4F39-4912-B18F-C678BD7C4906

Q35002396-0555B57A-963F-45BB-AC20-6357DB424CAC

Q35002396-064578F1-C4A6-4581-94E6-F965A7567731

Q35002396-0FD1A021-3B4D-485D-BBA9-A16D8B0FC01C

Q35002396-1459AEC4-A88F-44EA-B421-2776BFEE2997

Q35002396-15511AD1-33C3-4E88-B66E-17600ADF1072

Q35002396-17EFDACE-BFBC-4068-BD0D-9774DF9E4B42

Q35002396-200615FB-3A4E-41E1-B2DA-D5A34BABBD3C

Q35002396-20FD250E-4860-4744-ACF3-406C64831550

Q35002396-2124299B-1B44-4F90-B59C-1AEA684C4D8C

P2888

Q35002396-E6338F21-DF19-4845-8311-80D1A8CC0692

P304

Q35002396-CE0D41A7-FFE2-4CE4-BB16-6657F484FB44

P31

Q35002396-975BCEB8-5B40-44DC-B580-D79E1DF0CA40

P356

Q35002396-6C274EFF-524A-4365-9DB3-5726A1A822A0

P433

Q35002396-84598DE6-1C34-4CAD-B150-6FFDA91B8344

P478

Q35002396-5FE8B517-89D4-4BEB-882F-43528DFEC522

P50

Q35002396-2B0D785A-A437-4476-835A-D6D8559411CD

Q35002396-5CA1B0D8-F85F-47D7-BB6A-4CAD7F4BEB4D

Q35002396-BF568457-C4FC-46A4-8F73-585B8F86DA13

Q35002396-F1C85D20-738A-4080-94C0-21A9DAC0D0F9

P577

Q35002396-728A9B84-2060-4A51-B6BB-D1B98C7AB6F3

P5875

Q35002396-AD7E6C0B-E132-405C-AE00-895665CB9D48

P6179

Q35002396-C167223D-5E46-4B14-80FC-9A0FA96451ED

P698

Q35002396-C546369B-8A92-4282-A990-FE3CC3555030

P932

Q35002396-8E7BA219-09C8-427B-9015-6D8DC38F2413

P356

1472-6890-13-23

P1433

BMC Clinical Pathology

P1476

VRK2 identifies a subgroup of primary high-grade astrocytomas with a better prognosis

@en

P2093

Angel Santos-Briz

http://www.w3.org/2001/XMLSchema#string

Irene Rodríguez-Hernández

http://www.w3.org/2001/XMLSchema#string

Isabel F Fernández

http://www.w3.org/2001/XMLSchema#string

Juan A Gómez-Moreta

http://www.w3.org/2001/XMLSchema#string

Rogelio González-Sarmiento

http://www.w3.org/2001/XMLSchema#string

P2860

VRK2 inhibits mitogen-activated protein kinase signaling and inversely correlates with ErbB2 in human breast cancer

Characterization of three paralogous members of the Mammalian vaccinia related kinase family

c-Jun phosphorylation by the human vaccinia-related kinase 1 (VRK1) and its cooperation with the N-terminal kinase of c-Jun (JNK)

Plk3 interacts with and specifically phosphorylates VRK1 in Ser342, a downstream target in a pathway that induces Golgi fragmentation

p53 Stabilization and accumulation induced by human vaccinia-related kinase 1

Modulation of interleukin-1 transcriptional response by the interaction between VRK2 and the JIP1 scaffold protein

Vaccinia-related kinase 1 (VRK1) is an upstream nucleosomal kinase required for the assembly of 53BP1 foci in response to ionizing radiation-induced DNA damage

The subcellular localization of vaccinia-related kinase-2 (VRK2) isoforms determines their different effect on p53 stability in tumour cell lines

Human vaccinia-related kinase 1 (VRK1) activates the ATF2 transcriptional activity by novel phosphorylation on Thr-73 and Ser-62 and cooperates with JNK

Vaccinia-related kinase 2 modulates the stress response to hypoxia mediated by TAK1

P2888

1472-6890-13-23

P304

23

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1472-6890-13-23

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Javier Martín-Vallejo

Juan Luis García

Marta Vázquez-Cedeira

P577

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257247903

http://www.w3.org/2001/XMLSchema#string

P6179

1038620385

http://www.w3.org/2001/XMLSchema#string

P698

24079673

http://www.w3.org/2001/XMLSchema#string

P932

3849739

http://www.w3.org/2001/XMLSchema#string